GlassScriptPhysician profile
Joseph My
NPI 1174720734
$25,443.15
in general payments reported to CMS, 2019-2025
92 companies · $4,946 in 2025
The $4,946 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,883 · 2020: $2,483 · 2021: $2,811 · 2022: $3,041 · 2023: $4,319 · 2024: $3,960 · 2025: $4,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,463.39 |
| Education | $762.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,244.29 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Pfizer INC. | $2,230.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,895.72 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $1,695.39 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $1,386.74 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $1,014.02 | 2019-2025 | Adcetris, Tukysa, Padcev |
| Celgene Corporation | $986.29 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genentech USA, INC. | $936.30 | 2019-2025 | Tecentriq, Venclexta, Phesgo |
| Novartis Pharmaceuticals Corporation | $889.93 | 2019-2025 | |
| Genzyme Corporation | $857.65 | 2019-2025 | |
| Amgen INC. | $809.02 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Astellas Pharma US INC | $703.27 | 2019-2024 | Xtandi, Padcev |
| Abbvie INC. | $649.95 | 2019-2025 | |
| Incyte Corporation | $587.03 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $527.48 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 92 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $509.37 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $487.11 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Ipsen Biopharmaceuticals, INC | $453.60 | 2019-2025 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $387.43 | 2019-2025 | |
| Eisai INC. | $364.28 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $338.39 | 2019-2023 | Imbruvica, Epkinly |
| Coherus Oncology, INC. | $295.73 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $260.81 | 2019-2025 | Libtayo |
| Array Biopharma INC | $254.60 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Beone Medicines USA, INC. | $247.87 | 2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $221.15 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Jazz Pharmaceuticals INC. | $193.56 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $184.75 | 2020-2024 | Xpovio |
| Foundation Medicine, INC. | $175.90 | 2021-2023 | |
| Medtronic, INC. | $175.00 | 2024 | Osteocool Rf Ablation System |
| Alexion Pharmaceuticals, INC. | $170.92 | 2020-2025 | Ultomiris |
| Tempus Ai, INC | $169.68 | 2024-2025 | Xt Cdx |
| Beigene USA, INC. | $166.14 | 2022-2025 | Brukinsa |
| Taiho Oncology, INC. | $163.59 | 2019-2024 | |
| Dova Pharmaceuticals | $157.85 | 2019-2021 | |
| Sobi, INC | $136.28 | 2022-2024 | |
| Emd Serono, INC. | $130.37 | 2020-2025 | |
| Puma Biotechnology, INC. | $120.80 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $113.49 | 2023-2025 | |
| Gilead Sciences, INC. | $111.07 | 2023-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $96.99 | 2022-2025 | Besremi |
| Mirati Therapeutics, INC. | $85.55 | 2023 | Krazati |
| Kyowa Kirin, INC. | $81.10 | 2023-2025 | Poteligeo |
| Rigel Pharmaceuticals, INC. | $77.16 | 2019-2022 | |
| Exelixis INC. | $75.30 | 2019-2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.75 | 2019-2025 | |
| Fennec Pharmaceuticals, INC. | $73.34 | 2024-2025 | Pedmark, Fyarro |
| Caris Mpi, INC. | $68.64 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $65.88 | 2022-2024 | Odomzo, Yonsa |
| Adc Therapeutics America, INC. | $58.41 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $57.18 | 2023 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $56.59 | 2019-2022 | |
| Epizyme, INC. | $55.94 | 2020-2021 | |
| Morphosys, US INC. | $53.56 | 2021-2022 | |
| Stemline Therapeutics INC. | $49.95 | 2023-2025 | Orserdu |
| Clovis Oncology, INC. | $48.29 | 2020-2021 | |
| Elekta, INC. | $46.79 | 2025 | Elekta Medical Linear Accelerator |
| Tersera Therapeutics LLC | $46.58 | 2024-2025 | Zoladex |
| Sanofi-Aventis U.S. LLC | $46.37 | 2020-2025 | |
| Agios Pharmaceuticals, INC. | $40.29 | 2020-2024 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $40.12 | 2025 | Danziten, Vivimusta |
| Accord Healthcare, INC. | $39.69 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $39.37 | 2019 | |
| Legend Biotech USA INC. | $36.43 | 2025 | Carvykti |
| Novocure INC. | $35.29 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Recordati_rare_diseases_inc. | $34.58 | 2022-2024 | Sylvant |
| Verastem, INC. | $34.24 | 2020 | |
| Kite Pharma, INC. | $33.89 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $32.37 | 2025 | Provenge |
| Corcept Therapeutics | $27.22 | 2025 | Korlym |
| Mylan Institutional INC. | $24.93 | 2020 | |
| Biocon Biologics INC | $23.74 | 2025 | Ogivri |
| Emmaus Medical, INC. | $22.86 | 2020 | |
| Shire North American Group INC | $22.72 | 2019 | |
| Cti Biopharma Corp. | $22.21 | 2023 | Vonjo |
| Secura Bio, INC. | $21.47 | 2020 | |
| Amneal Pharmaceuticals LLC | $21.11 | 2025 | Alymsys |
| Tesaro, INC. | $21.05 | 2019 | |
| Heron Therapeutics, INC. | $20.66 | 2022 | |
| Acrotech Biopharma INC. | $20.41 | 2024 | Ryzneuta |
| Deciphera Pharmaceuticals INC. | $19.92 | 2025 | Qinlock, Romvimza |
| Eusa Pharma (US) LLC | $19.88 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.73 | 2022 | |
| Aurobindo Pharma USA, INC. | $19.36 | 2020 | |
| Aveo Pharmaceuticals, INC. | $18.97 | 2021 | |
| Genmab U.S., INC. | $18.71 | 2023 | Epkinly |
| Blue Earth Diagnostics | $18.35 | 2024 | |
| Partner Therapeutics, INC. | $15.34 | 2020 | |
| Pharmacosmos Therapeutics INC. | $15.19 | 2022 | |
| Myovant Sciences INC. | $14.86 | 2022 | |
| Acceleron Pharma, INC. | $13.52 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
Keytruda $877Tecvayli $605Reblozyl $567Erleada $528Xtandi $523Opdivo $469Darzalex $467Venclexta $461Adcetris $439Lynparza $382Elrexfio $363Sarclisa $336Talzenna $304Tukysa $298Jakafi $297Carvykti $286Brukinsa $286Talvey $274Tagrisso $270Ibrance $268Imbruvica $262Orgovyx $258Pluvicto $239Bosulif $223Inlyta $220Padcev $208Rybrevant $197Lenvima $177Osteocool Rf Ablation System $175Libtayo $171Xt Cdx $170Jaypirca $166Opdualag $165Tecentriq $164Enhertu $163Pomalyst $151Ultomiris $150Kisqali $138Braftovi $132Verzenio $118Zejula $115Tibsovo $113Trodelvy $111Lorbrena $101Zepzelca $96.26Lutathera $94.91Epkinly $91.45Tevimbra $90.07Krazati $85.55Jemperli $84.11Comirnaty $83.86Xpovio $83.84Mektovi $81.22Poteligeo $81.10Nubeqa $80.86Xofigo $80.86Ojjaara $79.02Inqovi $77.85Lonsurf $77.85Besremi $77.44Welireg $73.86Paxlovid $71.56Kyprolis $69.34Mi Cancer Seek $68.64Alunbrig $66.67Injectafer $64.10Doptelet $63.65Oxbryta $60.27Vectibix $54.02Xgeva $52.81Lumakras $51.78Orserdu $49.95Retevmo $47.71Keytruda Qlex $47.65Yonsa $47.48Pedmark $47.42Elekta Medical Linear Accelerator $46.79Zoladex $46.58Monjuvi $46.55Cablivi $44.35Fruzaqla $41.71Zynlonta $40.69Camcevi $39.69Piqray $38.10Eliquis $35.62Nplate $34.98Odomzo $34.33Provenge $32.37Bavencio $31.70Ninlaro $30.65Ayvakit $30.29Elahere $29.56Hyqvia $27.81Onivyde $27.35Korlym $27.22Datroway $27.14Tabrecta $26.67Fyarro $25.92Elitek $24.55Ogivri $23.74
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph My listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.